ischemic%20stroke
ISCHEMIC STROKE
Ischemic stroke occurs when a blood vessel supplying the brain is obstructed.
Consider stroke in any patient presenting with sudden focal neurological deficit or any alteration in level of consciousness.
Rapid evaluation is essential for sure of time-sensitive treatments.
Determine if patient's symptoms are due to stroke and exclude stroke mimics (eg migraine, hypertensive encephalopathy, hypoglycemia, seizures or post-ictal paresis); identify other conditions requiring immediate intervention and determine the potential causes of stroke.

Blood Pressure Management

  • Elevated blood pressure is a major risk factor for both 1st and subsequent stroke
  • Both elevated and low blood pressures are associated with poor outcome in acute ischemic stroke
  • Mild and moderately elevated blood pressure should not be routinely lowered in the acute phase of stroke as this may worsen outcome
    • Avoid aggressive blood pressure lowering as this is detrimental in acute stroke
  • Elevated blood pressure in stroke may be due to stress of cerebrovascular event, full bladder, nausea, pain, preexisting hypertension, physiological response to increased intracranial pressure or to hypoxia
  • Elevated blood pressure usually resolves spontaneously within the 1st few days after a stroke
  • Excessively high blood pressure is lowered to decrease brain edema formation, reduce risk of hemorrhagic transformation of the infarct, prevent further vascular damage and preclude early recurrent stroke

Blood Pressure Management [Non-Recombinant Tissue Plasminogen Activator (rt-PA) Patients]

  • Medications should be withheld unless systolic blood pressure (SBP) >220 mmHg or diastolic blood pressure (DBP) >120 mmHg or mean arterial pressure (MAP) >130
  • In patients with markedly elevated blood pressure, lower blood pressure by 10-15% during the first 24 hours after onset of stroke
  • Blood Pressure (mmHg) Treatment
    SBP >220 mmHg or

    DBP 121-140 mmHg

    Labetalol: 10-20 mg IV over 1-2 minutes

    May repeat or double the dose every 10 minutes

    Max dose: 300 mg in 24 hours

    or

    Nicardipine: Initially, 5 mg/hr IV infusion; titrate to desired effect by increasing 2.5 mg/hr every 5 minutes

    Max dose: 15 mg/hr

    (Aim for 10-15% decrease in blood pressure)

Blood Pressure Management (Pre-Thrombolytic Therapy)

  • Blood pressure management of patients eligible for thrombolysis is critical before and during the administration of recombination tissue plasminogen activator and during the ensuing 24 hours because severely elevated blood pressure is associated with parenchymal hemorrhage
  • Thrombolysis is not performed in patients with systolic blood pressure (SBP) >185 mmHg or diastolic blood pressure (DBP) >110 mmHg at the time of treatment
  • Correct blood pressure using the following:
  • Blood Pressure (mmHg) Treatment
    SBP >185 mmHg or

    DBP >110 mmHg

    Labetalol: 10-20 mg IV over 1-2 minutes; may repeat once

    or

    Nicardipine: 5 mg/hr IV infusion; titrate up to desired effect by 2.5 mg/hr at 5- to 15-minute intervals

    Max dose: 15 mg/hr

    When desired blood pressure is attained, adjust to maintain proper blood pressure level

  • If blood pressure is not reduced and remains >185/110 mmHg despite treatment, DO NOT GIVE recombinant tissue plasminogen activator
  • If medications are given to lower blood pressure, maintain the blood pressure level below 180/105 mmHg for at least the first 24 hours after IV recombinant tissue plasminogen activator treatment

Thrombolysis

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator (rt-PA)

  • Recombinant tissue plasminogen activator is the only thrombolytic proven effective in the treatment of acute ischemic stroke
  • Patients eligible for recombinant tissue plasminogen activator should be treated as quickly as possible within the time window as the benefits of recombinant tissue plasminogen activator diminish rapidly over time
  • Carefully selected patients may have improved outcomes if treated within extended window of 3 to 4.5 hours of stroke symptom onset
  • Intracranial hemorrhage can occur with use; risk can be reduced by careful selection of patients and presence of competent ancillary care
    • Signs and symptoms of intracerebral hemorrhage following recombinant tissue plasminogen activator include new headache, acute neurological deterioration, acute hypertension, nausea, or vomiting
    • Should intracerebral hemorrhage be suspected, discontinue recombinant tissue plasminogen activator and do CT scan or other tests to detect hemorrhage
    • Close monitoring of patient and immediate treatment of arterial hypertension are needed
  • Angioedema is also a potential side effect which may cause partial airway obstruction
  • Measure blood pressure and assess neurological status every 15 minutes during and after IV recombinant tissue plasminogen activator infusion for 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours after IV recombinant tissue plasminogen activator treatment
  • Thrombolysis can be done with 2 hours of continuous transcranial Doppler (TCD) monitoring, if available
  • Obtain follow-up CT or MRI at 24 hours after IV recombinant tissue plasminogen activator before starting anticoagulants or antiplatelet agents

Endovascular Interventions

  • Criteria for endovascular therapy with a stent retriever (all should be present):
    • A mRS score 0 to 1 prior to stroke
    • Acute ischemic stroke receiving intravenous recombinant tissue plasminogen activator within 4.5 hours of onset
    • Causative occlusion of the internal carotid artery or proximal middle cerebral artery
    • Age ≥18 years
    • NIHSS score of ≥ 6
    • Alberta Stroke Program Early CT score (ASPECTS) of ≥ 6
    • Treatment can be initiated (groin puncture) within 6 hours of symptom onset
  • Reduced time from symptom onset to reperfusion with endovascular therapies produces better clinical outcomes
    • Reperfusion to thrombolysis in cerebral infarction (TICI) grade 2b/3 should be achieved as early as possible and within 6 hours of stroke onset
    • It is not required to observe patients after IV recombinant tissue plasminogen activator to assess for clinical response before pursuing endovascular therapy to achieve beneficial outcomes

Other Options

  • Surgical (carotid end-arterectomy, mechanical thrombectomy)
  • Intra-arterial thrombolysis

Pharmacotherapy During and After Recombinant Tissue Plasminogen Activator Administration

  • Monitor blood pressure (BP) every 15 minutes for 2 hours from the start of recombinant tissue plasminogen activator therapy, then every 30 minutes for 6 hours, then every hour for the next 16 hours
  • Blood Pressure (mmHg) Treatment
    SBP > 180-230 mmHg or DBP >105-120 mmHg Labetalol: 10-20 mg IV over 2 minutes

    May repeat every 10-20 minutes

    Max dose: 300 mg in 24 hours

    or

    Labetalol: 10 mg IV followed by IV infusion at 2-8 mg/min

    Max dose: 300 mg in 24 hours

    SBP >230 mmHg or

    DBP 121-140 mmHg

    Labetalol: 10-20 mg IV over 2 minutes

    May repeat every 10-20 minutes

    Max dose: 300 mg in 24 hours

    or

    Labetalol: 10 mg IV followed by continuous IV infusion at 2-8 mg/min

    Max dose: 300 mg in 24 hours

    or

    Nicardipine: 5 mg/hr IV infusion initially, then titrate to desired effect by 2.5 mg/hr every 5-15 minutes

    Max dose: 15 mg/hr

  • If blood pressure is not controlled or diastolic BP >140 mmHg, consider sodium nitroprusside infusion at 0.5 mcg/kg/min (max dose: 10 mcg/kg/min)
  • If medications are given to lower BP, maintain the BP level below 180/105 mmHg for at least the first 24 hours after IV recombinant tissue plasminogen activator treatment

Pharmacotherapy

Other Therapeutic Measures

Antiplatelet Agents

Aspirin

  • Administered at a dose of 160-325 mg PO to most stroke patients and those who are not candidates for recombinant tissue plasminogen activator within 24-48 hours of stroke onset
    • For patients treated with recombinant tissue plasminogen activator, Aspirin should be given 24 hours after IV recombinant tissue plasminogen activator
    • Contraindicated in patients with Aspirin allergy or suffering from gastrointestinal bleeding
  • Should not be used as a substitute if patient qualifies for other acute interventions (eg recombinant tissue plasminogen activator)
  • Shown to prevent early recurrent stroke within 14 days of acute ischemic stroke
    • Reduces stroke mortality and morbidity

Anticoagulant Agents

Heparins

  • Eg Unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and heparinoids
  • Routine anticoagulation is not recommended
  • Should not be used in lieu of recombinant tissue plasminogen activator for treatment of otherwise eligible patients
  • Administration within 24 hours of recombinant tissue plasminogen activator is not recommended due to increased risk of bleeding complications
  • Subcutaneous UFH and LMWH may be considered for deep venous thrombosis (DVT) prophylaxis in at-risk patients
    • Non-pharmacologic treatments for deep venous thrombosis prevention may also be used
    • Risk vs benefit of pharmacologic agents needs to be considered
  • Not shown to decrease mortality and morbidity nor prevent stroke recurrence
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Even small risk reductions achieved with improved air quality afford health benefits similar to that gained with smoking and systolic hypertension control, according to a study in an urban China population.
4 days ago
The degree of left atrial (LA) remodeling predicts atrial tachycardia (AT) recurrence rather than atrial fibrillation (AF) recurrence following catheter ablation of AF, a recent study has shown.
13 Jun 2017
Both haemorrhagic and ischaemic stroke patients benefit similarly from a conventional therapy combined with robotic-assisted gait training (RAGT) intervention regimen, a new study shows.
Tristan Manalac, 3 days ago
Consumption of peanuts, walnuts and tree nuts appears to reduce the risk of coronary heart disease (CHD) and cardiovascular disease (CVD), according to recent large prospective cohort studies.